Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,711
archived clinical trials in
Depression

ICU Family Communication Study
A Randomized Trial of an Interdisciplinary Communication Intervention to Improve Patient and Family Outcomes in the Intensive Care Unit
Status: Enrolling
Updated:  6/25/2013
Virginia Mason Medical Center
2007
mi
from 43215
Seattle, WA
ICU Family Communication Study
A Randomized Trial of an Interdisciplinary Communication Intervention to Improve Patient and Family Outcomes in the Intensive Care Unit
Status: Enrolling
Updated: 6/25/2013
Virginia Mason Medical Center
2007
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
ICU Family Communication Study
A Randomized Trial of an Interdisciplinary Communication Intervention to Improve Patient and Family Outcomes in the Intensive Care Unit
Status: Enrolling
Updated:  6/25/2013
University of Washington Medical Center
2005
mi
from 43215
Seattle, WA
ICU Family Communication Study
A Randomized Trial of an Interdisciplinary Communication Intervention to Improve Patient and Family Outcomes in the Intensive Care Unit
Status: Enrolling
Updated: 6/25/2013
University of Washington Medical Center
2005
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Trial of Collaborative Depression Care Management for HIV Patients
Strategies to Link Antidepressant and Antiretroviral Management at Duke, UAB and UNC
Status: Enrolling
Updated:  6/26/2013
University of Alabama at Birmingham 1917 Clinic
492
mi
from 43215
Birmingham, AL
Trial of Collaborative Depression Care Management for HIV Patients
Strategies to Link Antidepressant and Antiretroviral Management at Duke, UAB and UNC
Status: Enrolling
Updated: 6/26/2013
University of Alabama at Birmingham 1917 Clinic
492
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Trial of Collaborative Depression Care Management for HIV Patients
Strategies to Link Antidepressant and Antiretroviral Management at Duke, UAB and UNC
Status: Enrolling
Updated:  6/26/2013
University of North Carolina Hospitals Infectious Diseases Clinic
353
mi
from 43215
Chapel Hill, NC
Trial of Collaborative Depression Care Management for HIV Patients
Strategies to Link Antidepressant and Antiretroviral Management at Duke, UAB and UNC
Status: Enrolling
Updated: 6/26/2013
University of North Carolina Hospitals Infectious Diseases Clinic
353
mi
from 43215
Chapel Hill, NC
Click here to add this to my saved trials
Trial of Collaborative Depression Care Management for HIV Patients
Strategies to Link Antidepressant and Antiretroviral Management at Duke, UAB and UNC
Status: Enrolling
Updated:  6/26/2013
Duke University Clinic 2J
354
mi
from 43215
Durham, NC
Trial of Collaborative Depression Care Management for HIV Patients
Strategies to Link Antidepressant and Antiretroviral Management at Duke, UAB and UNC
Status: Enrolling
Updated: 6/26/2013
Duke University Clinic 2J
354
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
1985
mi
from 43215
Redondo Beach, CA
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
1985
mi
from 43215
Redondo Beach, CA
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
2091
mi
from 43215
San Jose, CA
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
2091
mi
from 43215
San Jose, CA
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
1981
mi
from 43215
Sherman Oaks, CA
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
1981
mi
from 43215
Sherman Oaks, CA
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
980
mi
from 43215
Hallandale Beach, FL
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
980
mi
from 43215
Hallandale Beach, FL
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
428
mi
from 43215
Smyrna, GA
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
428
mi
from 43215
Smyrna, GA
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
622
mi
from 43215
Prairie Village, KA
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
622
mi
from 43215
Prairie Village, KA
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
337
mi
from 43215
Baltimore, MD
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
337
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
480
mi
from 43215
New York, NY
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
469
mi
from 43215
Staten Island, NY
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
469
mi
from 43215
Staten Island, NY
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
369
mi
from 43215
Raleigh, NC
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
369
mi
from 43215
Raleigh, NC
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
130
mi
from 43215
Beachwood, OH
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
130
mi
from 43215
Beachwood, OH
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
998
mi
from 43215
Houston, TX
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
998
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
1514
mi
from 43215
Murray, UT
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
1514
mi
from 43215
Murray, UT
Click here to add this to my saved trials
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated:  7/8/2013
Clinical Research Facility
2001
mi
from 43215
Kirkland, WA
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022 AM3)
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder
Status: Enrolling
Updated: 7/8/2013
Clinical Research Facility
2001
mi
from 43215
Kirkland, WA
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
1973
mi
from 43215
Los Angeles, CA
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
1973
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
993
mi
from 43215
Miami, FL
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
993
mi
from 43215
Miami, FL
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
411
mi
from 43215
Athens, GA
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
411
mi
from 43215
Athens, GA
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
323
mi
from 43215
Bethesda, MD
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
323
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
618
mi
from 43215
Kansas City, MO
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
618
mi
from 43215
Kansas City, MO
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
444
mi
from 43215
Bridgewater, NJ
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
444
mi
from 43215
Bridgewater, NJ
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
478
mi
from 43215
Brooklyn, NY
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
478
mi
from 43215
Brooklyn, NY
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
89
mi
from 43215
Cincinnati, OH
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
89
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
362
mi
from 43215
Chattanooga, TN
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
362
mi
from 43215
Chattanooga, TN
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
937
mi
from 43215
Fort Worth, TX
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
937
mi
from 43215
Fort Worth, TX
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
1512
mi
from 43215
American Fork, UT
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
1512
mi
from 43215
American Fork, UT
Click here to add this to my saved trials
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated:  7/12/2013
Clinical Research Facility
330
mi
from 43215
Burlington, WI
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
Status: Enrolling
Updated: 7/12/2013
Clinical Research Facility
330
mi
from 43215
Burlington, WI
Click here to add this to my saved trials
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated:  7/16/2013
Genova Clinical Research
1640
mi
from 43215
Tucson, AZ
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated: 7/16/2013
Genova Clinical Research
1640
mi
from 43215
Tucson, AZ
Click here to add this to my saved trials
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated:  7/16/2013
Osteoporosis Medical Center
mi
from 43215
Beverly Hills, CA
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated: 7/16/2013
Osteoporosis Medical Center
mi
from 43215
Beverly Hills, CA
Click here to add this to my saved trials
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated:  7/16/2013
SDS Clinical Trials
1959
mi
from 43215
Orange, CA
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated: 7/16/2013
SDS Clinical Trials
1959
mi
from 43215
Orange, CA
Click here to add this to my saved trials
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated:  7/16/2013
Research Across America
1960
mi
from 43215
Santa Ana, CA
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated: 7/16/2013
Research Across America
1960
mi
from 43215
Santa Ana, CA
Click here to add this to my saved trials
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated:  7/16/2013
Innovative Research of West Florida, Inc.
830
mi
from 43215
Clearwater, FL
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated: 7/16/2013
Innovative Research of West Florida, Inc.
830
mi
from 43215
Clearwater, FL
Click here to add this to my saved trials
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated:  7/16/2013
Florida Medical Center & Research, Inc.
mi
from 43215
Coral Gables, FL
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated: 7/16/2013
Florida Medical Center & Research, Inc.
mi
from 43215
Coral Gables, FL
Click here to add this to my saved trials
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated:  7/16/2013
Meridien Research
839
mi
from 43215
St Petersburg, FL
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated: 7/16/2013
Meridien Research
839
mi
from 43215
St Petersburg, FL
Click here to add this to my saved trials
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated:  7/16/2013
Medical Research and Health Education Foundation, Inc.
mi
from 43215
Columbus, GA
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated: 7/16/2013
Medical Research and Health Education Foundation, Inc.
mi
from 43215
Columbus, GA
Click here to add this to my saved trials
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated:  7/16/2013
Heartland Research Associates, LLC
781
mi
from 43215
Wichita, KA
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated: 7/16/2013
Heartland Research Associates, LLC
781
mi
from 43215
Wichita, KA
Click here to add this to my saved trials
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated:  7/16/2013
Central Kentucky Research Associates, Inc.
154
mi
from 43215
Lexington, KY
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated: 7/16/2013
Central Kentucky Research Associates, Inc.
154
mi
from 43215
Lexington, KY
Click here to add this to my saved trials
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated:  7/16/2013
Boston Clinical Trials, INC.
643
mi
from 43215
Boston, MA
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated: 7/16/2013
Boston Clinical Trials, INC.
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated:  7/16/2013
Michigan Head Pain & Neurological Institute
163
mi
from 43215
Ann Arbor, MI
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated: 7/16/2013
Michigan Head Pain & Neurological Institute
163
mi
from 43215
Ann Arbor, MI
Click here to add this to my saved trials
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated:  7/16/2013
Quality Clinical Research, Inc.
688
mi
from 43215
Omaha, NE
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated: 7/16/2013
Quality Clinical Research, Inc.
688
mi
from 43215
Omaha, NE
Click here to add this to my saved trials
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated:  7/16/2013
Social Psychiatry Research Institute
479
mi
from 43215
Brooklyn, NY
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated: 7/16/2013
Social Psychiatry Research Institute
479
mi
from 43215
Brooklyn, NY
Click here to add this to my saved trials
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated:  7/16/2013
University of Cincinnati
98
mi
from 43215
Cincinnati, OH
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated: 7/16/2013
University of Cincinnati
98
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated:  7/16/2013
Radiant Research, Inc.
109
mi
from 43215
Akron, OH
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated: 7/16/2013
Radiant Research, Inc.
109
mi
from 43215
Akron, OH
Click here to add this to my saved trials
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated:  7/16/2013
Midwest Clinical Research Center
65
mi
from 43215
Dayton, OH
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
A Phase 3b Multicenter, Double-Blind, Randomized, Placebo-Controlled, 2-Way Crossover Study of Pregabalin in the Treatment of Fibromyalgia With Concurrent Antidepressant Therapy for Comorbid Depression
Status: Enrolling
Updated: 7/16/2013
Midwest Clinical Research Center
65
mi
from 43215
Dayton, OH
Click here to add this to my saved trials